Justin Klee co-founded Amylyx Pharmaceuticals (NASDAQ: AMLX) in 2013 and continues to serve as its co-CEO. Justin, alongside co-CEO Josh Cohen, has overseen the growth of Amylyx -- from its start as a concept dreamed up in a dorm room through its IPO, FDA and Health Canada approvals of its first product, and product launch -- to the company it is today, with a mission to usher in a new era for treating diseases with high unmet needs.
Justin co-invented the oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO, also known as ursodoxicoltaurine), which is being explored for the potential treatment of neurodegenerative diseases. Amylyx’ clinical trial results in collaboration with leading experts have been published in several peer-reviewed medical journals, including the New England Journal of Medicine, Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry.
In 2020, Justin and Josh were named to Business Insider’s 30 Under 40 in Healthcare list and PM360’s ELITE in the Drug Researchers and Developers category. Amylyx was also selected as one of Fierce Biotech’s 2020 Fierce 15 companies. Justin and Josh were named to PM360’s 2022 ELITE Entrepreneurs list, were awarded the Harvey and Bonny Gaffen Advancements in ALS Award by the Les Turner Foundation in 2022, and received the Henri Termeer Transatlantic Connections Award the same year. The CENTAUR clinical trial team made up of Amylyx, the MGH Neurological Clinical Research Institute, the Northeast ALS Consortium, and Barrow Neurological Institute was also awarded the 2022 Annual Healey Center International Prize for Innovation in ALS, an award that recognizes excellence in research for an individual or team who catalyze exceptional discoveries leading to a transformative therapy development in ALS. Justin and Josh were also awarded the Northeast ALS Consortium (NEALS) Big Data Award in 2022 for their application of real world evidence approaches in ALS clinical research.
Justin previously conducted research in neural systems in the Moore lab at Brown University and in neurophysiology and Alzheimer’s disease under Dr. Rudolph Tanzi, founding member of Amylyx’ Scientific Advisory Board, at Harvard Medical School to explore new approaches to treating relentlessly progressive neurodegenerative diseases. Justin holds his Bachelor of Science in neuroscience from Brown and is a published author in several high impact journals including Nature.
What is Justin B. Klee's net worth?
The estimated net worth of Justin B. Klee is at least $48.18 million as of September 30th, 2025. Klee owns 3,325,301 shares of Amylyx Pharmaceuticals stock worth more than $48,183,611 as of December 4th. This net worth evaluation does not reflect any other assets that Klee may own. Additionally, Klee receives an annual salary of $1,080,000.00 as CEO at Amylyx Pharmaceuticals. Learn More about Justin B. Klee's net worth.
How old is Justin B. Klee?
What is Justin B. Klee's salary?
How do I contact Justin B. Klee?
Has Justin B. Klee been buying or selling shares of Amylyx Pharmaceuticals?
Justin B. Klee has not been actively trading shares of Amylyx Pharmaceuticals within the last three months. Most recently, Justin B. Klee sold 29,975 shares of the business's stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $14.38, for a transaction totalling $431,040.50. Following the completion of the sale, the chief executive officer now directly owns 3,325,301 shares of the company's stock, valued at $47,817,828.38. Learn More on Justin B. Klee's trading history.
Who are Amylyx Pharmaceuticals' active insiders?
Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amylyx Pharmaceuticals?
In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company.
Learn More about insider trades at Amylyx Pharmaceuticals. Information on this page was last updated on 12/1/2025.
